Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice.
The availability of a murine model of Pompe disease has enabled an evaluation of the relative merits of various therapeutic paradigms, including gene therapy. We report here that administration of a recombinant adeno-associated virus serotype 8 (AAV8) vector (AAV8/DC190-GAA) encoding human acid alpha-glucosidase (GAA) into presymptomatic Pompe mice resulted in nearly complete correction of the lysosomal storage of glycogen in all the affected muscles. A relatively high dose of AAV8/DC190-GAA was necessary to attain a threshold level of GAA for inducing immunotolerance to the expressed enzyme and for correction of muscle function, coordination, and strength. Administration of AAV8/DC190-GAA into older Pompe mice with overt disease manifestations was also effective at correcting the lysosomal storage abnormality. However, these older mice exhibited only marginal improvements in motor function and no improvement in muscle strength. Examination of histologic sections showed evidence of skeletal muscle degeneration and fibrosis in aged Pompe mice whose symptoms were abated or rescued by early but not late treatment with AAV8/DC190-GAA. These results suggest that AAV8-mediated hepatic expression of GAA was effective at addressing the biochemical and functional deficits in Pompe mice. However, early therapeutic intervention is required to maintain significant muscle function and should be an important consideration in the management and treatment of Pompe disease.
Ziegler
Robin J
RJ
Genzyme, Framingham, MA 01701, USA.
Bercury
Scott D
SD
Fidler
Jonathan
J
Zhao
Michael A
MA
Foley
Joseph
J
Taksir
Tatyana V
TV
Ryan
Susan
S
Hodges
Bradley L
BL
Scheule
Ronald K
RK
Shihabuddin
Lamya S
LS
Cheng
Seng H
SH
D000818:Animals; D000229:Dependovirus; D004195:Disease Models, Animal; D005822:Genetic Vectors; D006009:Glycogen Storage Disease Type II / Q000150:complications / Q000503:physiopathology* / Q000628:therapy*; D006801:Humans; D008099:Liver / Q000201:enzymology*; D008112:Liver Glycogen / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008817:Mice, Mutant Strains; D009043:Motor Activity; D018482:Muscle, Skeletal / Q000473:pathology / Q000503:physiopathology; D009135:Muscular Diseases / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D000520:alpha-Glucosidases / Q000097:blood / Q000235:genetics*
D008112:Liver Glycogen; D000520:alpha-Glucosidases